Lars Möllgård
Impact in
- Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 35
- Acute Myeloid Leukemia Research 34
- Chronic Myeloid Leukemia Treatments 7
- Hematopoietic Stem Cell Transplantation 4
- Genetics 14
- Chronic Lymphocytic Leukemia Research 8
- Myeloproliferative Neoplasms: Diagnosis and Treatment 5
- Hemoglobinopathies and Related Disorders 4
- Co-authors
- Gunnar JuliussonMartin HöglundAnders WåhlinÅsa Rangert DerolfDick StockelbergUlf TidefeltPetar AntunovićSylvain Lehmann
In The Last Decade
Lars Möllgård
41 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Hematology 1.5k
- Genetics 627
- Oncology 531
- Public Health, Environmental and Occupational Health 516
- Pathology and Forensic Medicine 289
Countries citing papers authored by Lars Möllgård
This map shows the geographic impact of Lars Möllgård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Möllgård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Möllgård more than expected).
Fields of papers citing papers by Lars Möllgård
This network shows the impact of papers produced by Lars Möllgård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Möllgård. The network helps show where Lars Möllgård may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lars Möllgård, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2022 | 12 | |
| 3 | 2022 | 21 | |
| 4 | 2019 | 17 | |
| 5 | 2019 | 22 | |
| 6 | 2017 | 40 | |
| 7 | 2014 | 41 | |
| 8 | 2011 | 46 | |
| 9 | 2011 | 43 | |
| 10 | Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Hit paper breakdown → | 2008 | 683 |
| 11 | 2008 | 26 | |
| 12 | 2007 | 28 | |
| 13 | 2007 | 7 | |
| 14 | 2005 | 6 | |
| 15 | 2003 | 37 | |
| 16 | 2003 | 8 | |
| 17 | No additional toxicity from cladribine (CdA) when given with cytosin arabinoside and idarubicin (CCI) as primary treatment of acute myeloid leukemia in elderly patients : Results from a randomized phase II-study from the leukemia group of middle Sweden (LGMS). | 2001 | 3 |
| 18 | 2001 | 4 | |
| 19 | 2000 | 22 | |
| 20 | 1998 | 6 |
About Lars Möllgård
Lars Möllgård is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Oncology and Molecular Biology, having authored 41 papers that have together received 2.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (34 papers), Acute Lymphoblastic Leukemia research (17 papers), Chronic Lymphocytic Leukemia Research (8 papers), Retinoids in leukemia and cellular processes (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Hemoglobinopathies and Related Disorders (4 papers) and Hematopoietic Stem Cell Transplantation (4 papers). The work is most often cited by research in Hematology (1.5k citations), Genetics (627 citations), Oncology (531 citations), Public Health, Environmental and Occupational Health (516 citations) and Pathology and Forensic Medicine (289 citations). Lars Möllgård has collaborated with scholars based in Sweden, Denmark and Norway. Frequent co-authors include Gunnar Juliusson, Martin Höglund, Anders Wåhlin, Åsa Rangert Derolf, Dick Stockelberg, Ulf Tidefelt, Petar Antunović, Sylvain Lehmann, Sören Lehmann and Lovisa Wennström. Their work appears in journals such as Blood, British Journal of Haematology, Haematologica, European Journal Of Haematology and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.